Albert Einstein College of Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Albert Einstein College of Medicine sits in the top decile of US sponsors by registered trial count (#169 of 15,742 sponsors by registered trial count).

175 total trials 20 currently recruiting 121 completed early-phase tilt top decile by trial count

Albert Einstein College of Medicine: 175 sponsored US clinical trials, 20 recruiting.

Albert Einstein College of Medicine sponsors 175 registered US clinical trials on ClinicalTrials.gov, 20 of them currently recruiting, and 121 completed. 17 of these trials are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Pain, with 5 trials.

Top-decile sponsor footprint

Albert Einstein College of Medicine ranks in the top decile of sponsors by registered trial count (#169 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

121 of 148 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

175 total, page 3 of 4

COMPLETED NA

Wellness Program Implementation: School & Student Toolkits

NCT02277496

COMPLETED Phase 2

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer

NCT02073968

TERMINATED NA

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT01897441

COMPLETED NA

Effectiveness and Feasibility of Patient Controlled Analgesia in the ED

NCT01775371

COMPLETED NA

A Trial To Study The Effects Of Group Versus Individual Dietary Counseling In Pediatric Obesity

NCT01840631

TERMINATED Phase 1

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT01408160

COMPLETED Phase 4

Neurocognitive Effects of Opiate Agonist Treatment

NCT01733693

COMPLETED Phase 2

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

NCT01755416

COMPLETED Phase 1

Comparison of Standard Versus Low Bicarbonate Hemodialysis

NCT01777178

COMPLETED NA

Pilot Test of a Community-based Buprenorphine Treatment Intervention

NCT01761110

COMPLETED Phase 2

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

NCT01772420

COMPLETED NA

Efficacy of Group Attachment Based Intervention for Vulnerable Families

NCT01641744

COMPLETED Phase 2

Cardiac Surgery Neuroprotection Study in Elders

NCT01561378

TERMINATED NA

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

NCT01589926

COMPLETED NA

Project FIRST - Financial Incentives to Reduce Substance Use and Improve Treatment

NCT01376570

TERMINATED Phase 3

Treatment of Strongyloides Infection

NCT03605758

COMPLETED NA

Chinese Diabetes Prevention Program (Chinese DPP)

NCT02277509

COMPLETED Phase 2

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01605032

COMPLETED

Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents

NCT01840618

TERMINATED Phase 2

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

NCT01897454

COMPLETED Phase 4

Sitagliptin Dose Determination Study

NCT01530178

COMPLETED Phase 2

HIPEC for Peritoneal Carcinomatosis

NCT02040142

TERMINATED NA

Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer

NCT03648983

COMPLETED Phase 2

Association Between Body Size and Response to Hydromorphone in ED

NCT01675778

COMPLETED Phase 2

Alkali Therapy in Chronic Kidney Disease

NCT01452412

TERMINATED NA

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301

COMPLETED NA

Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients

NCT01378858

COMPLETED NA

Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance

NCT01375959

COMPLETED Phase 1

Closed Loop System With Pramlintide Versus Exenatide

NCT01269008

COMPLETED Phase 4

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034

TERMINATED Phase 1

Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates

NCT00609154

COMPLETED NA

LUCHAR - Latinos Using Counseling for Help With Asthma and Anxiety Reduction

NCT01583296

TERMINATED

Sickle Cell Trait and the Risk of Venous Thromboembolism

NCT01148940

TERMINATED NA

Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy

NCT01939210

COMPLETED

Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users

NCT01108679

COMPLETED Phase 3

The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease

NCT01029002

COMPLETED Phase 4

Smoking Cessation Treatment for Methadone Maintenance Patients

NCT01027754

COMPLETED Phase 4

Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

NCT01269047

COMPLETED NA

Project Prepared: Risks, Roles and Relationships

NCT01880450

COMPLETED NA

Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department

NCT00910208

COMPLETED Phase 2

Effect of Vitamin D Repletion on Insulin Resistance and Systemic Inflammation

NCT01354964

COMPLETED Phase 2

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

NCT00888290

TERMINATED Phase 2

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer

NCT01041027

COMPLETED Phase 1

Intravenous Gammaglobulin for Sickle Cell Pain Crises

NCT01757418

COMPLETED Phase 1

Allergy Immunotherapy for the Reduction of Asthma

NCT01028560

COMPLETED NA

Bronx A1c: Bring it Down for Health

NCT00797888

COMPLETED Phase 4

Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery

NCT01439802

COMPLETED Phase 2

Pemetrexed and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01001910

COMPLETED NA

A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer

NCT00754286

COMPLETED NA

Acupuncture for Chronic Pain

NCT01149317

← Previous Page 3 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 20
Phase 2 29
Phase 3 5
Phase 4 12

What is open in the Albert Einstein College of Medicine pipeline

20 recruiting of 175 indexed (11% open); 121 completed (69%).

Phase mix: 17 late (III/IV) vs 49 early (I/II) (early-phase heavy).

Top condition: Chronic Pain (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Albert Einstein College of Medicine: open-pipeline peers nationwide

Peers matched on 175 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20% Total trials Recruiting share Albert Einstein College of MedicineBausch & Lomb IncorporatedUConn HealthBaylor Research InstituteAbbottUniversity of MemphisChildren's Mercy Hospital Kansas CityJanssen Research & DevelopmentBarbara Ann Karmanos Cancer Institute
Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Albert Einstein College of Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 175 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Albert Einstein College of Medicine page

175 registered trials is a research-attention snapshot, not an endorsement of Albert Einstein College of Medicine or any single study.

  • 20 of Albert Einstein College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Chronic Pain is the condition Albert Einstein College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Albert Einstein College of Medicine pipeline card: 175 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.